Monoclonal Antibody Infusion Using Regeneron

Monoclonal antibody infusions have been proven to be an effective treatment for patients presenting with mild to moderate Covid symptoms, and who are at high risk of developing serious complications. The infusion does not work as a vaccine, but rather prevents the virus from replicating which has reduced hospitalizations across the country. From November 2020 through mid-April 2021, Bamlanivimab was most commonly used but it was recalled by the FDA on April 16th 2021. Now, providers have turned to Regeneron (casirivimab and imdevimab) to continue providing this infusion treatment in the hopes of staving off ICU stays. Getting reimbursed for this service is easy; here are the codes:

• M0243: Outpatient (not including the home) intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring

• M0244: Home or residence intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring

• Q0244: Injection, casirivimab and imdevimab, 1200 mg

Make sure you use the Covid ICD-10 code (U07.1) when billing this service. The Q-code should be billed at $.01 as it is required for some payers and only used for reporting purposes; the medication itself is provided free of charge from the government. Also, keep in mind that this should be billed directly to the Medicare contractor in your region and not to any Medicare Advantage Plan in which a patient may be enrolled.

If you have any questions regarding billing for these services, contact us today.

Premier Medical Billing, LLC

www.premiermbma.com